(Q36379330)

13 August 2017

1 reference

title

Tigecycline: a novel glycylcycline antibiotic (English)

1 reference

13 August 2017

1

George G Zhanel

1 reference

13 August 2017

2

James A Karlowsky

1 reference

13 August 2017

Ethan Rubinstein

3

1 reference

PubMed ID

16441206

13 August 2017

Daryl J Hoban

series ordinal

4

1 reference

13 August 2017

1 February 2006

1 reference

Expert Review of Anti-infective Therapy

13 August 2017

1 reference

13 August 2017

4

1 reference

13 August 2017

9-25

1 reference

13 August 2017

1

1 reference

Controlling antimicrobial resistance in hospitals: infection control and use of antibiotics

13 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Antimicrobial stewardship programs as a means to optimize antimicrobial use. Insights from the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Antimicrobial resistance trends and outbreak frequency in United States hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Trends in antimicrobial drug development: implications for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: results from the SENTRY antimicrobial surveillance program, 1997-98. SENTR

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Grou

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Methicillin-resistant Staphylococcus aureus disease in three communities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Newer treatment options for skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Glycylcyclines: third-generation tetracycline antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

The glycylcyclines: a comparative review with the tetracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Ertapenem: review of a new carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

A critical review of the fluoroquinolones: focus on respiratory infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

In vitro activity of tigecycline against ampicillin-resistant Haemophilus influenzae isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

In vitro activities of tigecycline against the Bacteroides fragilis group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Pharmacokinetics of ertapenem in healthy young volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.9

21 January 2018

Identifiers

DOI

10.1586/14787210.4.1.9

1 reference

13 August 2017

1 reference

PubMed ID

16441206